Chinese Pharma Companies Seem Fairly Immune to U.S. Policy Risk -- Market Talk

Dow Jones

10/08

0244 GMT - Chinese pharma companies are unlikely to face much risk from U.S. President Trump's policies, Citi analysts say in a note. Multinationals are poised to keep investing in Chinese biotech assets due to their high potential, cost-effectiveness and good clinical data, among other reasons, John Yung and others write. They believe the Trump administration may have difficulty restricting U.S. firms from acquiring or forming partnerships with China-developed assets--which they need to grow product pipelines. Any such restrictions could cause U.S. pharma companies to lose out on early-stage assets, they add. Citi's top sector picks include Jiangsu Hengrui Pharmaceuticals, Hansoh Pharmaceutical Group and Ascletis Pharma. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

October 07, 2025 22:44 ET (02:44 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573915160"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573915160\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573915160?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 10:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573915160","market":"us","top_or_hot":-1,"title":"Chinese Pharma Companies Seem Fairly Immune to U.S. Policy Risk -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0244 GMT - Chinese pharma companies are unlikely to face much risk from U.S. President Trump's policies, Citi analysts say in a note. Multinationals are poised to keep investing in Chinese biotech assets due to their high potential, cost-effectiveness and good clinical data, among other reasons, John Yung and others write. They believe the Trump administration may have difficulty restricting U.S. firms from acquiring or forming partnerships with China-developed assets--which they need to grow product pipelines. Any such restrictions could cause U.S. pharma companies to lose out on early-stage assets, they add. Citi's top sector picks include <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals, Hansoh Pharmaceutical Group and <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma</a>. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2025 22:44 ET (02:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Companies Seem Fairly Immune to U.S. Policy Risk -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Companies Seem Fairly Immune to U.S. Policy Risk -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-08 10:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0244 GMT - Chinese pharma companies are unlikely to face much risk from U.S. President Trump's policies, Citi analysts say in a note. Multinationals are poised to keep investing in Chinese biotech assets due to their high potential, cost-effectiveness and good clinical data, among other reasons, John Yung and others write. They believe the Trump administration may have difficulty restricting U.S. firms from acquiring or forming partnerships with China-developed assets--which they need to grow product pipelines. Any such restrictions could cause U.S. pharma companies to lose out on early-stage assets, they add. Citi's top sector picks include <a href=\"https://laohu8.com/S/600276\">Jiangsu Hengrui</a> Pharmaceuticals, Hansoh Pharmaceutical Group and <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma</a>. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2025 22:44 ET (02:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573915160","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573915160","pubTimestamp":1759891440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0244 GMT - Chinese pharma companies are unlikely to face much risk from U.S. President Trump's policies, Citi analysts say in a note. Multinationals are poised to keep investing in Chinese biotech assets due to their high potential, cost-effectiveness and good clinical data, among other reasons, John Yung and others write. They believe the Trump administration may have difficulty restricting U.S. firms from acquiring or forming partnerships with China-developed assets--which they need to grow product pipelines. Any such restrictions could cause U.S. pharma companies to lose out on early-stage assets, they add. Citi's top sector picks include Jiangsu Hengrui Pharmaceuticals, Hansoh Pharmaceutical Group and Ascletis Pharma. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","BK0239":"医药制造","BK1583":"高瓴概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0183":"MSCI概念","BK1589":"北水核心资产","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0188":"融资融券","BK0012":"证金概念","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","01672":"歌礼制药-B","BK0028":"国家队","BK1191":"制药","BK1161":"生物科技","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0060":"抗癌","03692":"翰森制药","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK1515":"抗疫概念","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1574":"生物医药B类股","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0196":"行业龙头"},"translate_title":"中国制药公司似乎相当不受美国政策风险的影响——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"01672":0.9,"03692":0.9},"content_text":"0244 GMT - Chinese pharma companies are unlikely to face much risk from U.S. President Trump's policies, Citi analysts say in a note. Multinationals are poised to keep investing in Chinese biotech assets due to their high potential, cost-effectiveness and good clinical data, among other reasons, John Yung and others write. They believe the Trump administration may have difficulty restricting U.S. firms from acquiring or forming partnerships with China-developed assets--which they need to grow product pipelines. Any such restrictions could cause U.S. pharma companies to lose out on early-stage assets, they add. Citi's top sector picks include Jiangsu Hengrui Pharmaceuticals, Hansoh Pharmaceutical Group and Ascletis Pharma. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 07, 2025 22:44 ET (02:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}